| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3161 | 2019 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2025 | 2017 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709, 2017 | 1077 | 2017 |
| Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma D Miao, CA Margolis, W Gao, MH Voss, W Li, DJ Martini, C Norton, ... Science 359 (6377), 801-806, 2018 | 1020 | 2018 |
| Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ... Cancer cell 33 (5), 843-852. e4, 2018 | 942 | 2018 |
| Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures Y Şenbabaoğlu, RS Gejman, AG Winer, M Liu, EM Van Allen, ... Genome biology 17, 1-25, 2016 | 792 | 2016 |
| Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ... Journal of Clinical Oncology 35 (34), 3851, 2017 | 468 | 2017 |
| Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network AA Hakimi, I Ostrovnaya, B Reva, N Schultz, YB Chen, M Gonen, H Liu, ... Clinical Cancer Research 19 (12), 3259-3267, 2013 | 381 | 2013 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 307 | 2022 |
| Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). A Amin, ER Plimack, JR Infante, MS Ernstoff, BI Rini, DF McDermott, ... Journal of Clinical Oncology 32 (15_suppl), 5010-5010, 2014 | 291 | 2014 |
| An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma AA Hakimi, H Furberg, EC Zabor, A Jacobsen, N Schultz, G Ciriello, ... Journal of the National Cancer Institute 105 (24), 1862-1870, 2013 | 285 | 2013 |
| Tumor microenvironment dynamics in clear-cell renal cell carcinoma L Vuong, RR Kotecha, MH Voss, AA Hakimi Cancer discovery 9 (10), 1349-1357, 2019 | 283 | 2019 |
| Hereditary leiomyomatosis and renal cell carcinoma syndrome–associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant … YB Chen, AR Brannon, A Toubaji, ME Dudas, HH Won, HA Al-Ahmadie, ... The American journal of surgical pathology 38 (5), 627-637, 2014 | 263 | 2014 |
| Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma AA Hakimi, YB Chen, J Wren, M Gonen, O Abdel-Wahab, A Heguy, H Liu, ... European urology 63 (5), 848-854, 2013 | 261 | 2013 |
| The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) BI Rini, D Battle, RA Figlin, DJ George, H Hammers, T Hutson, E Jonasch, ... Journal for immunotherapy of cancer 7, 1-20, 2019 | 227 | 2019 |
| Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy MH Voss, AA Hakimi, CG Pham, AR Brannon, YB Chen, LF Cunha, ... Clinical cancer research 20 (7), 1955-1964, 2014 | 225 | 2014 |
| Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy C Krishna, RG DiNatale, F Kuo, RM Srivastava, L Vuong, D Chowell, ... Cancer cell 39 (5), 662-677. e6, 2021 | 219 | 2021 |
| Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) H Hammers, ER Plimack, JR Infante, M Ernstoff, BI Rini, DF McDermott, ... Annals of Oncology 25, iv361, 2014 | 209 | 2014 |
| Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma JJ Hsieh, D Chen, PI Wang, M Marker, A Redzematovic, YB Chen, ... European urology 71 (3), 405-414, 2017 | 208 | 2017 |
| Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial AA Hakimi, MH Voss, F Kuo, A Sanchez, M Liu, BG Nixon, L Vuong, ... Cancer discovery 9 (4), 510-525, 2019 | 198 | 2019 |
